CA2121889A1 - Production and use of multimeric hemoglobins - Google Patents
Production and use of multimeric hemoglobinsInfo
- Publication number
- CA2121889A1 CA2121889A1 CA002121889A CA2121889A CA2121889A1 CA 2121889 A1 CA2121889 A1 CA 2121889A1 CA 002121889 A CA002121889 A CA 002121889A CA 2121889 A CA2121889 A CA 2121889A CA 2121889 A1 CA2121889 A1 CA 2121889A1
- Authority
- CA
- Canada
- Prior art keywords
- hemoglobin
- tetramers
- tetramer
- monodisperse
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
Abstract
The present invention relates to multimeric hemoglobin-like proteins wherein two or more tetramers or pseudotetramers are covalently bonded. Between any pair of covalently linked tetramers, the covalent linkage may take the form of a crosslink between two cysteine residues of different polypeptide chain, or of a peptide linker connecting the "carboxy most" residue of a globin-like domain of one tetramer with the "amino most" residue of a similar domain of a second tetramer. Preferably, the multimeric hemoglobin-like protein-containing composition is at least 50% monodisperse, more preferably, at least 95% monodisperse. Although free hemoglobin purified from natural sources may be polymerized by chemical crosslinking to increase halflife via increased molecular weight, and to reduce oncotic pressure, all such preparations are heterogeneous. Monodispersability can be achieved only by laborious purification. The present invention provides means of exerting strict control over the degree of polymerization of hemoglobin tetramers. The ability to strictly control formation of multimers will greatly facilitate purification and characterization of the final product and will reduce the chance of adverse reaction to minor components. It is also believed that a more mono-disperse composition will have greater consistency of clinical effect.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US789,179 | 1991-11-08 | ||
US07/789,179 US5545727A (en) | 1989-05-10 | 1991-11-08 | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
PCT/US1992/009752 WO1993009143A1 (en) | 1991-11-08 | 1992-11-06 | Production and use of multimeric hemoglobins |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2121889A1 true CA2121889A1 (en) | 1993-05-13 |
CA2121889C CA2121889C (en) | 2001-08-21 |
Family
ID=25146814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002121889A Expired - Fee Related CA2121889C (en) | 1991-11-08 | 1992-11-06 | Production and use of multimeric hemoglobins |
Country Status (13)
Country | Link |
---|---|
US (7) | US5545727A (en) |
EP (2) | EP0611376B1 (en) |
JP (1) | JPH07501059A (en) |
AT (1) | ATE167485T1 (en) |
AU (1) | AU672960B2 (en) |
CA (1) | CA2121889C (en) |
DE (1) | DE69225978T2 (en) |
FI (1) | FI942138A (en) |
HU (1) | HUT70309A (en) |
IL (2) | IL119656A0 (en) |
NO (1) | NO941703L (en) |
SG (1) | SG47882A1 (en) |
WO (1) | WO1993009143A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112662677A (en) * | 2021-03-02 | 2021-04-16 | 天津师范大学 | Chironomus rubripes Hb gene and application thereof in water quality biological monitoring |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US5844090A (en) * | 1994-05-09 | 1998-12-01 | Somatogen, Inc. | Modified hemoglobin-like compounds |
US6150506A (en) * | 1989-05-10 | 2000-11-21 | Baxter Biotech Technology Sarl | Modified hemoglobin-like compounds and methods of purifying same |
US6828125B1 (en) * | 1989-05-10 | 2004-12-07 | Baxter Biotech Technology, S.A.R.L. | DNA encoding fused di-alpha globins and use thereof |
US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
AU665599B2 (en) * | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
AU694111B2 (en) * | 1993-03-31 | 1998-07-16 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
US5939391A (en) * | 1993-03-31 | 1999-08-17 | Pro-Neuron, Inc. | Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation |
US6610654B2 (en) | 1993-03-31 | 2003-08-26 | Wellstat Therapeutics Corporation | Inhibitor of stem cell proliferation and uses thereof |
IS4198A (en) * | 1993-08-13 | 1995-02-14 | Somatogen, Inc | Treatment for side effects associated with extracellular hemoglobin administration |
US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
WO1997023631A2 (en) * | 1995-12-22 | 1997-07-03 | Somatogen, Inc. | Globins containing binding domains |
AU715914B2 (en) | 1995-12-22 | 2000-02-10 | Baxter Biotech Technology S.A.R.L. | Globins containing binding domains |
US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
JP2000516455A (en) | 1996-08-02 | 2000-12-12 | バクスター バイオテック テクノロジー エス.アー.エール.エル. | Methods for controlling beta-dimer formation in hemoglobin |
JP2001501473A (en) * | 1996-09-27 | 2001-02-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | Oxygen-binding heme protein incorporating cyclically modified globin |
AU4990697A (en) * | 1996-10-18 | 1998-05-15 | Eli Lilly And Company | Methods of reducing the levels of protoporphyrin ix in recombinant hemoglobin preparations |
EP0966480A2 (en) | 1997-01-30 | 1999-12-29 | The University Of Virginia Patent Foundation | Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor |
US6054427A (en) * | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
EP1950298A3 (en) | 1997-05-02 | 2008-12-24 | Baxter Biotech Technology S.A.R.L. | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
DE69839263T2 (en) | 1997-05-02 | 2009-04-30 | Baxter Biotech Technology S.A.R.L. | Hemoglobin mutants with reduced nitrogen (mon) oxide removal capacity |
US6780892B1 (en) | 1998-10-01 | 2004-08-24 | Temple University—Of the Commonwealth System of Higher Education | Polymeric hemoglobin mutants |
WO2000018802A1 (en) * | 1998-10-01 | 2000-04-06 | Temple University - Of The Commonwealth System Of Higher Education | Polymeric hemoglobin mutants |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
EP2292657A1 (en) | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
US7164035B2 (en) * | 2000-01-07 | 2007-01-16 | Newsome David A | Zinc-monocysteine complex and method of using zinc-cysteine complexes |
AU2001278117A1 (en) * | 2000-08-03 | 2002-02-18 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
US6645767B1 (en) * | 2000-10-03 | 2003-11-11 | Carnegie Mellon University | Cells engineered to contain genes of interest without expressed bacterial sequences and materials and methods therefor |
US8008459B2 (en) * | 2001-01-25 | 2011-08-30 | Evolva Sa | Concatemers of differentially expressed multiple genes |
WO2002061113A2 (en) * | 2001-02-01 | 2002-08-08 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
NZ527590A (en) * | 2001-03-09 | 2005-12-23 | Genentech Inc | Process for production of polypeptides |
US20040133468A1 (en) * | 2002-04-12 | 2004-07-08 | Varghese Kivin G. | Method and system for providing interactive adversing cross reference to related application |
US7238777B2 (en) * | 2001-10-16 | 2007-07-03 | Asahi Kasei Kabushiki Kaisha | Agents for adsorption and bridging for adenovirus |
EP1431244A4 (en) * | 2001-11-08 | 2004-08-04 | Matsushita Electric Ind Co Ltd | Micrograin film and process for producing the same |
US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
US20030153491A1 (en) * | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
JP3912206B2 (en) * | 2002-07-05 | 2007-05-09 | 株式会社日立製作所 | Fuel pump for in-cylinder direct fuel injection system |
WO2004009242A2 (en) * | 2002-07-22 | 2004-01-29 | Mba Polymers, Inc. | Mediating electrostatic separations |
US7998705B2 (en) * | 2002-08-06 | 2011-08-16 | FUJIFILM Diosynth Biotechnologies U.S.A., Inc | Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol |
MXPA05007163A (en) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Maleamic acid polymer derivatives and their bioconjugates. |
EP1644048B1 (en) * | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
ES2393555T3 (en) | 2003-10-22 | 2012-12-26 | Keck Graduate Institute | Methods for the synthesis of hetero-multimeric polypeptides in yeasts using a haploid mating strategy. |
WO2005074521A2 (en) * | 2004-01-30 | 2005-08-18 | The Trustees Of Columbia University In The City Of New York | C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF |
CA2594040A1 (en) * | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
JP2008528004A (en) * | 2005-01-26 | 2008-07-31 | ザ ジョンズ ホプキンス ユニバーシティー | Anticancer DNA vaccine using plasmid encoding mutant oncoprotein antigen and calreticulin |
US20090155875A1 (en) * | 2005-02-16 | 2009-06-18 | Massachusetts Institute Of Technology | Methods to Enhance Carbon Monoxide Dehydrogenase Activity and Uses Thereof |
US8318474B1 (en) * | 2005-05-23 | 2012-11-27 | California Institute Of Technology | Engineered yeast cells and uses thereof |
US20100330105A1 (en) * | 2006-08-22 | 2010-12-30 | John Hopkins University | Anticancer Combination Therapies |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
RU2010102859A (en) * | 2007-08-21 | 2011-09-27 | Морфосис Аг (De) | IMPROVED METHODS FOR THE FORMATION OF DISULPHIDE LINKS |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
EP2571991A1 (en) | 2010-05-20 | 2013-03-27 | Evolva SA | Method of producing isoprenoid compounds in yeast |
WO2012012352A2 (en) * | 2010-07-19 | 2012-01-26 | Amidebio, Llc | Modified peptides and proteins |
US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
US10752672B1 (en) * | 2019-02-01 | 2020-08-25 | Cheer Global Limited | Recombinant hemoglobins and methods of preparation and use thereof |
CN113087787B (en) * | 2021-05-19 | 2023-03-21 | 广西医科大学第二附属医院(广西医科大学第二临床医学院) | Earthworm hemoglobin separation and purification method |
WO2023102156A1 (en) | 2021-12-03 | 2023-06-08 | Wisconsin Alumni Research Foundation | Mutant ace2 proteins and methods of using same |
CN116203144B (en) * | 2022-05-11 | 2023-10-27 | 重庆医科大学附属儿童医院 | Method for determining chain ratio of various globin in hemoglobin and application thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2449885C3 (en) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process |
US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4769326A (en) * | 1980-02-29 | 1988-09-06 | The Regents Of The University Of California | Expression linkers |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4551433A (en) * | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4473496A (en) * | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
DE3144705C2 (en) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the production of a storage-stable, cross-linked hemoglobin preparation with high oxygen transport capacity, as well as the hemoglobin preparation produced by this process |
US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4599197A (en) * | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4713339A (en) * | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
US4738952A (en) * | 1984-04-27 | 1988-04-19 | Synthetic Blood Corporation | Substitute for human blood and a method of making the same |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4774180A (en) * | 1986-02-26 | 1988-09-27 | Massachusetts Institute Of Technology | Construction and application of polyproteins |
US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
DE3515252C2 (en) * | 1985-04-27 | 1994-02-24 | Roehm Gmbh | Process for the immobilization of dissolved proteins |
DE3675588D1 (en) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4730936A (en) * | 1986-10-10 | 1988-03-15 | The United States Of America As Represented By The Secretary Of The Air Force | Gas driven system for preparing large volumes of non-oxidized, pyridoxylated, polymerized stroma-free hemoglobin solution for use as a blood substitute |
DE3636590A1 (en) * | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | BLOOD REPLACEMENT |
WO1988006601A1 (en) * | 1987-03-02 | 1988-09-07 | Genex Corporation | Gene repressors |
GB8710598D0 (en) * | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
GB8711614D0 (en) * | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
US5049493A (en) * | 1987-10-23 | 1991-09-17 | California Institute Of Technology | Enhancement of cell growth by expression of a cloned hemoglobin gene |
EP0319206A3 (en) * | 1987-11-30 | 1990-04-18 | Berlex Laboratories, Inc. | Gene amplification |
IL87708A (en) * | 1988-09-08 | 1994-04-12 | Technion Inst For Research And | Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof |
DE69034091T2 (en) * | 1989-05-10 | 2004-04-22 | Baxter Biotech Technology S.A.R.L. | Production of hemoglobin and analogues thereof in non-erythrocyte cells |
NL8901174A (en) * | 1989-05-10 | 1990-12-03 | Het Hoofd Van De Afdeling Mili | HEMOGLOBINE PREPARATION AND USE THEREOF. |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
EP0537160B1 (en) * | 1990-04-16 | 2002-08-21 | Apex Bioscience, Inc. | Expression of recombinant hemoglobin in yeast |
JPH06504056A (en) * | 1990-12-20 | 1994-05-12 | ザ・ユニバーシティ・オブ・アラバマ・リサーチ・ファウンデーション | Transgenic cross-linked hemoglobin |
US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
-
1991
- 1991-11-08 US US07/789,179 patent/US5545727A/en not_active Expired - Fee Related
-
1992
- 1992-11-06 DE DE69225978T patent/DE69225978T2/en not_active Expired - Fee Related
- 1992-11-06 JP JP5508788A patent/JPH07501059A/en active Pending
- 1992-11-06 AT AT92925173T patent/ATE167485T1/en not_active IP Right Cessation
- 1992-11-06 CA CA002121889A patent/CA2121889C/en not_active Expired - Fee Related
- 1992-11-06 SG SG1996004964A patent/SG47882A1/en unknown
- 1992-11-06 EP EP92925173A patent/EP0611376B1/en not_active Expired - Lifetime
- 1992-11-06 HU HU9401338A patent/HUT70309A/en unknown
- 1992-11-06 AU AU31337/93A patent/AU672960B2/en not_active Ceased
- 1992-11-06 WO PCT/US1992/009752 patent/WO1993009143A1/en active IP Right Grant
- 1992-11-06 EP EP97203723A patent/EP0857489A3/en not_active Withdrawn
-
1994
- 1994-05-06 NO NO941703A patent/NO941703L/en not_active Application Discontinuation
- 1994-05-09 FI FI942138A patent/FI942138A/en unknown
-
1995
- 1995-05-19 US US08/444,939 patent/US5801019A/en not_active Expired - Fee Related
- 1995-05-19 US US08/444,942 patent/US5744329A/en not_active Expired - Lifetime
- 1995-05-19 US US08/444,915 patent/US6274331B1/en not_active Expired - Fee Related
- 1995-05-19 US US08/446,105 patent/US5798227A/en not_active Expired - Lifetime
- 1995-05-19 US US08/444,991 patent/US5844088A/en not_active Expired - Fee Related
- 1995-05-25 US US08/450,733 patent/US5844089A/en not_active Expired - Lifetime
-
1996
- 1996-11-20 IL IL11965696A patent/IL119656A0/en unknown
- 1996-11-20 IL IL11965796A patent/IL119657A0/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112662677A (en) * | 2021-03-02 | 2021-04-16 | 天津师范大学 | Chironomus rubripes Hb gene and application thereof in water quality biological monitoring |
Also Published As
Publication number | Publication date |
---|---|
FI942138A0 (en) | 1994-05-09 |
WO1993009143A1 (en) | 1993-05-13 |
DE69225978T2 (en) | 1999-02-11 |
EP0857489A2 (en) | 1998-08-12 |
FI942138A (en) | 1994-06-29 |
EP0857489A3 (en) | 1998-09-30 |
HU9401338D0 (en) | 1994-08-29 |
EP0611376A1 (en) | 1994-08-24 |
AU3133793A (en) | 1993-06-07 |
US5844088A (en) | 1998-12-01 |
US5801019A (en) | 1998-09-01 |
IL119656A0 (en) | 1997-02-18 |
US5545727A (en) | 1996-08-13 |
NO941703D0 (en) | 1994-05-06 |
DE69225978D1 (en) | 1998-07-23 |
IL119657A0 (en) | 1997-02-18 |
ATE167485T1 (en) | 1998-07-15 |
SG47882A1 (en) | 1998-04-17 |
US6274331B1 (en) | 2001-08-14 |
HUT70309A (en) | 1995-09-28 |
JPH07501059A (en) | 1995-02-02 |
NO941703L (en) | 1994-07-04 |
US5844089A (en) | 1998-12-01 |
AU672960B2 (en) | 1996-10-24 |
EP0611376B1 (en) | 1998-06-17 |
US5744329A (en) | 1998-04-28 |
US5798227A (en) | 1998-08-25 |
CA2121889C (en) | 2001-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2121889A1 (en) | Production and use of multimeric hemoglobins | |
DE68916932D1 (en) | ANTIMICROBIAL PEPTIDES, COMPOSITIONS CONTAINING THEM AND USES THEREOF. | |
EP1197220A3 (en) | Therapeutic methods and compositions based on delta proteins and nucleic acids | |
WO1995021919A3 (en) | Protein having tpo activity | |
MXPA03001469A (en) | Synthetic erythropoiesis stimulating proteins. | |
Mestecky et al. | Site of attachment of J chain to human immunoglobulin M | |
Van Damme et al. | The Urtica dioica agglutinin is a complex mixture of isolectins | |
EP0422125A4 (en) | Platelet blocking peptides | |
WO1999005270A3 (en) | Crustacean antimicrobial peptides, called penaiedines | |
ATE256185T1 (en) | T-CELL MEMBRANE PROTEIN (TIRC7), PEPTIDES AND ANTIBODIES DERIVED THEREOF, AND USES THEREOF | |
AU617039B2 (en) | Protein anti-cancer agent | |
IL99079A (en) | Amino acid and dna sequences of gelonin | |
US5349054A (en) | Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin | |
JPS62502540A (en) | Compositions containing purified interferon | |
CA2162193A1 (en) | Lactoferrin receptor protein | |
Kino et al. | Purification and characterization of three mitogenic lectins from the roots of pokeweed (Phytolacca americana) | |
JPH0873499A (en) | New peptide and immunopotentiator | |
SE8801723D0 (en) | FIBRONECTIN BINDING PROTEIN AS WELL AS IT'S PREPARATION | |
Marti et al. | Hb Altdorf α2β2 135 (H13) Ala→ Pro: A new electrophoretically silent unstable haemoglobin variant from Switzerland | |
WO2003014293A3 (en) | Novel polypeptide analogs and fusions and their methods of use | |
KR910018405A (en) | Bradykinin-antagonistic Peptides | |
CA2035389C (en) | Bacteriocin peptide | |
Peri et al. | Bis [2-(4-carboxyphenoxy) carbonylethyl] phosphinic acid (BCCEP): a new reagent for hemoglobin modification | |
Ströder et al. | The cold-insoluble fibrinogen fraction of bovine and human plasma | |
NO994806L (en) | Peptide fragments of myelin basic protein, their pharmaceutical preparations and their use in the treatment of multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |